
Sundial Growers SNDL
$ 1.37
0.74%
Annual report 2025
added 03-21-2026
Sundial Growers Interest Expense 2011-2026 | SNDL
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Sundial Growers
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 81 K | 178 K | 40 K | 7.77 M | 14.4 M | 2.92 M | - | - | - | - | - | - | - |
All numbers in CAD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 14.4 M | 40 K | 4.23 M |
Interest Expense of other stocks in the Drug manufacturers industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AcelRx Pharmaceuticals
ACRX
|
1.12 M | - | 7.5 % | $ 6.35 M | ||
|
Alimera Sciences
ALIM
|
10.2 M | - | - | $ 142 M | ||
|
Aerie Pharmaceuticals
AERI
|
-27.9 M | - | - | $ 754 M | ||
|
Agile Therapeutics
AGRX
|
1.42 M | - | 10.11 % | $ 58.2 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
4.92 K | - | 0.86 % | $ 117 M | ||
|
China Pharma Holdings
CPHI
|
27.4 K | $ 0.57 | -9.62 % | $ 9.95 M | ||
|
Catalent
CTLT
|
-4 M | - | - | $ 11.5 B | ||
|
Pacira BioSciences
PCRX
|
-373 K | $ 23.2 | 2.43 % | $ 1.07 B | ||
|
Athenex
ATNX
|
25.8 M | - | -23.39 % | $ 1.76 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
13 M | - | - | $ 2.06 B | ||
|
Perrigo Company plc
PRGO
|
-13.2 M | $ 9.64 | 0.73 % | $ 1.34 B | ||
|
DURECT Corporation
DRRX
|
2.24 M | - | - | $ 50.1 M | ||
|
Emergent BioSolutions
EBS
|
87.9 M | $ 8.01 | -0.5 % | $ 410 M | ||
|
Endo International plc
ENDP
|
350 M | - | - | $ 28.9 M | ||
|
Evoke Pharma
EVOK
|
500 K | - | - | $ 36.6 M | ||
|
Rockwell Medical
RMTI
|
2.3 M | $ 1.03 | 0.98 % | $ 24 M | ||
|
HEXO Corp.
HEXO
|
20.1 M | - | 2.45 % | $ 38.1 M | ||
|
SCYNEXIS
SCYX
|
3.13 M | $ 0.9 | 2.8 % | $ 44.9 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
606 K | $ 3.13 | 2.62 % | $ 44 M | ||
|
Solid Biosciences
SLDB
|
824 K | $ 6.68 | -6.44 % | $ 585 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
-10 K | $ 2.34 | -8.24 % | $ 2.9 M | ||
|
Bausch Health Companies
BHC
|
-28 M | $ 4.99 | -2.16 % | $ 1.82 B | ||
|
Harrow Health
HROW
|
47 K | $ 35.2 | 3.53 % | $ 1.29 B | ||
|
Tilray
TLRY
|
46.6 M | $ 6.66 | 3.26 % | $ 4.12 B | ||
|
OptiNose
OPTN
|
19.5 M | - | - | $ 1.08 B | ||
|
Evolus
EOLS
|
-539 K | $ 4.43 | -5.34 % | $ 286 M | ||
|
Veru
VERU
|
862 K | $ 2.29 | -0.43 % | $ 309 M | ||
|
Eagle Pharmaceuticals
EGRX
|
4.04 M | - | -39.89 % | $ 27.7 M | ||
|
Viatris
VTRS
|
573 M | $ 13.36 | 0.53 % | $ 16 B | ||
|
Relmada Therapeutics
RLMD
|
5.15 M | $ 6.1 | 4.1 % | $ 241 M | ||
|
PetIQ
PETQ
|
38.3 M | - | 1.64 % | $ 400 M | ||
|
ProPhase Labs
PRPH
|
764 K | - | - | $ 5.07 M | ||
|
Jupiter Wellness
JUPW
|
-5.37 M | - | - | $ 33.6 M | ||
|
TherapeuticsMD
TXMD
|
300 K | $ 2.29 | -0.87 % | $ 23.9 M | ||
|
Radius Health
RDUS
|
18.3 M | - | - | $ 1.42 B | ||
|
Lannett Company
LCI
|
58 M | - | 1.15 % | $ 7.11 M | ||
|
cbdMD
YCBD
|
-29.5 K | $ 0.77 | 1.06 % | $ 3.32 M | ||
|
Organogenesis Holdings
ORGO
|
20 K | $ 2.41 | -2.43 % | $ 317 M | ||
|
Neoleukin Therapeutics
NLTX
|
12 K | - | - | $ 193 M | ||
|
Canopy Growth Corporation
CGC
|
74.6 M | $ 0.96 | -0.87 % | $ 103 M | ||
|
Assertio Holdings
ASRT
|
2.78 M | $ 16.51 | 17.93 % | $ 106 M | ||
|
Recro Pharma
REPH
|
9.96 M | - | -4.76 % | $ 65.3 M | ||
|
Tricida
TCDA
|
17.6 M | - | - | $ 3.25 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
80.2 K | - | - | $ 55.5 M |